CAS: 898271-20-0; 1-Boc-(3-Aminoethyl)Azetidine
该化合物是一种化学化合物,其特点是其芳香环结构,即由四人组成的饱和热循环化合物,内含一个氮原子.该物质在安眠环的1个位置上具有二甲基组特征,有助于其不育的体积,并可能影响其反应和相互作用.一个碳箱式功能组的存在表明它可以参与各种化学反应,包括酯化和恐吓.此外,氨基乙基氨基副链表明它有可能参与生物活动,因为氨基乙基乙基化合物往往与生物宏观分子相互作用.该化合物的独特结构可能赋予特定特性,例如极溶剂中的溶性以及形成氢结的能力.
相似化合物
1170905-43-7 1337879-35-2 162696-31-3物理性质
MSDS等安全信息
欧盟法规
ECHA物质C&L通报上下游产品
Tert-Butyl 3-(2-Amino-2-Oxoethyl)Azetidine-1-Carboxylate 898271-19-73-(2-羟基乙基)氮杂丁烷-1-羧酸叔丁酯 Tert-Butyl 3-(2-Hydroxyethyl)Azetidine-1-Carboxylate 152537-03-6
合成工艺路线路线简述
📜Tert-Butyl 3-(2-Amino-2-Oxoethyl)Azetidine-1-Carboxylate置于dimethyl Sulfide Borane,碘,N,N-二异丙基乙胺体系中,用 四氢呋喃,甲醇 作为反应溶剂,化学反应 6.0H,以53.5%的收率获得产物1-叔丁氧羰基-3-氨基乙基氮杂
参考文献:Wo2006/73366
标题:Wo2006/73366
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2912110000-甲醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
专利号:CN-118147098-B
优先权日:2024-04-22
标题 :Leucine dehydrogenase mutants and their applications in the synthesis of chiral nitrogen heterocyclic amines
专利号:WO-2022162606-A1
优先权日:2021-01-30
标 题:Heterocyclic compounds as kinase inhibitor and uses thereof
发明人：YAN ZHIYU; WANG XIAOHUI; LIU HANLAN; KHAN PASHA M; PANPATIL DAYANAND; PUJALA BRAHMAM; PENDHARKAR DHANANJAY; JADHAVAR PRADEEP S; SAEED UZMA; KUMAR VIVEK
权利人:SPEROGENIX THERAPEUTICS LTD; INTEGRAL BIOSCIENCES PRIVATE LTD
摘要:The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (J), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes such as cancer, idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed. Formula (J)
